Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

Overview of attention for article published in Frontiers in endocrinology, September 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 10 X users

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 11 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 10 X posts from 10 X users, with an upper bound of 13,548 followers.

RT @GtoSemi: Frontiers | Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patie…

18 Oct 2021

Reply Repost Favourite

Frontiers | Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment | Endocrinology https://t.co/gVWJqaPsrJ

17 Oct 2021

Reply Repost Favourite

RT @Osteoporosis_NL: Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients…

13 Oct 2021

Reply Repost Favourite

RT @Osteoporosis_NL: Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients…

13 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 6 additional X posts.